Back to Results
First PageMeta Content
Chronic lower respiratory diseases / Chronic obstructive pulmonary disease / Smoking / Phosphodiesterase-4 inhibitor / Acute exacerbation of chronic obstructive pulmonary disease / Roflumilast / Spirometry / Tiotropium bromide / Pulmonology / Respiratory therapy / Medicine


Briefing Book - April 2010
Add to Reading List

Open Document

File Size: 1,62 MB

Share Result on Facebook

City

City / /

Company

Briefing Book - DAXAS (roflumilast) Forest Research Institute Inc. / ITT / /

Currency

pence / /

Event

FDA Phase / /

Facility

Plaza V Jersey City / /

MedicalCondition

RATIONALE FOR USE OF ROFLUMILAST IN COPD / Pivotal COPD / Previous and Concurrent Diseases / COPD / CONCLUSIONS FROM THE PIVOTAL ROFLUMILAST COPD STUDIES / COPD BACKGROUND / /

Organization

FDA / Pulmonary-Allergy Drugs Advisory Committee / Forest Research Institute / /

Position

EXECUTIVE / /

Product

M2-111 / DAXAS® (roflumilast) / /

ProvinceOrState

New Jersey / /

Technology

PHARMACOKINETICS / /

SocialTag